Centre For Research Excellence In Prostate Cancer Survivorship (CRE-PCS)
Funder
National Health and Medical Research Council
Funding Amount
$2,498,842.00
Summary
The Centre for Research Excellence in Prostate Cancer Survivorship will 1) develop, evaluate and translate responsive, equitable and accessible survivorship interventions for men with prostate cancer and their partners and families in high need areas 2) support evidence-based policy and practice in prostate cancer survivorship care 3) train and equip the workforce and its leaders to ensure translation and sustainably improve the underpinning health care and other relevant systems.
The Tasmanian Healthy Brain Project: A Longitudinal Intervention Study To Reduce The Risk Of Ageing-related Cognitive Decline And Dementia
Funder
National Health and Medical Research Council
Funding Amount
$878,792.00
Summary
It has been proposed that engagement in purposeful complex mental stimulation provides protection against dementia. The Tasmanian Healthy Brain Project (THBP) is a unique, large-scale prospective trial that examines whether university-level study in older adult population reduces ageing-related cognitive decline and risk of dementia. This project will also examine how an individual’s genetic profile may influence the potential benefits of complex mental stimulation as well as risk of dementia.
STudy Of Risk Assessment To Reduce Complications In Patients Following Noncardiac SurgerY (STRATIFY)
Funder
National Health and Medical Research Council
Funding Amount
$436,000.00
Summary
Cardiac problems account for many complications in patients undergoing major non-cardiac surgery, and even apparently minor cardiac damage is a marker of high risk for subsequent adverse events. Unfortunately, while money and effort is expended on identifying patients at risk, the appropriate response to this risk is quite unclear. The performance of bypass surgery or balloon angioplasty in order to treat the underlying coronary disease of at-risk patients is used in other situations, and reduce ....Cardiac problems account for many complications in patients undergoing major non-cardiac surgery, and even apparently minor cardiac damage is a marker of high risk for subsequent adverse events. Unfortunately, while money and effort is expended on identifying patients at risk, the appropriate response to this risk is quite unclear. The performance of bypass surgery or balloon angioplasty in order to treat the underlying coronary disease of at-risk patients is used in other situations, and reduces longterm risk. However, in many patients undergoing major noncardiac surgery, this approach may be inappropriately aggressive, as these patients are often elderly, have other diseases that make heart operations more difficult and risky than usual, and in any case may have a reduced life expectancy from the disease necessitating the operation. As the most critical issue is to ensure that patients undergo their surgery uneventfully, an alternative is the use of intensive medical therapy to protect the heart. This multicentre study, based at Brisbane hospitals that perform large numbers of major operations, will follow up patients for complications, and outcome (including quality of life) will be assessed six months after the operation. We will address two important questions about the efficacy and cost of risk reduction strategies. First, in patients at higher levels of risk and with a positive stress test, could a combination of medical therapy designed to protect the heart be as effective as current approaches, which include the performance of bypass surgery or coronary balloon angioplasty? Second, in patients identified as being at some risk - but low risk - are drugs sufficiently effective to avoid the need for further testing to quantify risk? As the population continues to age, the numbers of at risk patients undergoing major surgery will increase, and answers to these questions will provide important information to guide their management.Read moreRead less
Enhancing Erythropoietin Therapy In Ischaemia-reperfusion Injury Of Heart And Kidney
Funder
National Health and Medical Research Council
Funding Amount
$361,021.00
Summary
Heart attacks and kidney disease from a lack of blood flow are common causes of morbidity and have poor treatment options. Erythropoietin (epo) is a useful new treatment, but there remain some caveats to its use in humans: eg. it may cause excessive scarring during repair. Use of epo with an anti-inflammatory drug may decrease scarring and provide benefit to long-term health. We plan to carefully define the biomolecular pathways of injury and repair, to better plan this therapy for human use.